Revenue From Contracts With Customers was Schrodinger’s largest product and service line in fiscal 2025, bringing in $183.51M of $253.25M (72%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Revenue From Contracts With Customers | — | $157.32M | — | $183.51M | |||
| On-Premise Software | $84.49M | — | $104.02M | — | |||
| On Premise Software | — | — | — | — | |||
| Drug Discovery Services | $43.43M | — | $25.74M | $30.00M | |||
| Drug Discovery | — | — | — | — | |||
| Oncology, Neurology, & Immunology Product | $22.10M | $43.20M | $10.80M | $2.80M | |||
| Software Maintenance | — | — | $23.28M | $27.29M | |||
| Hosted Software | $14.89M | $20.38M | $35.25M | — | |||
| Drug Discovery Services Revenue From Contracts With Customers | — | — | — | — | |||
| Professional Services | $15.21M | — | $9.80M | $9.65M | |||
| Software Contribution | — | — | — | — | |||
| Total | $180.11M | $220.91M | $208.89M | $253.25M |
Schrodinger brought in $253.25M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. Schrodinger regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $208.89M. Revenue From Contracts With Customers was the largest at $183.51M (72.5%), ahead of Drug Discovery Services at $30.00M (11.8%) and Software Maintenance at $27.29M (10.8%). The other two lines brought in $12.45M combined.
Compared with fiscal 2024, Software Maintenance grew fastest, up 17.2% to $27.29M, while Professional Services fell the most, down 1.5% to $9.65M.
Schrodinger began breaking out Revenue From Contracts With Customers in fiscal 2023, when it brought in $157.32M. Schrodinger stopped reporting On-Premise Software ($104.02M in fiscal 2024) and Hosted Software ($35.25M in fiscal 2024) as separate lines.
United States was Schrodinger’s largest region in fiscal 2025, bringing in $152.96M of $255.87M (60%).
| Geography | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| United States | $123.56M | $161.96M | $114.87M | $152.96M | |||
| Emea | $34.45M | $29.14M | $65.65M | $75.16M | |||
| Apac | $21.68M | $24.57M | $25.80M | $26.18M | |||
| Europe | — | — | — | — | |||
| Japan | — | — | — | — | |||
| Rest Of World | $1.27M | $1.00M | $1.22M | $1.56M | |||
| Total | $180.96M | $216.67M | $207.54M | $255.87M |
Schrodinger brought in $255.87M from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 23.3% from $207.54M in fiscal 2024. United States was the largest at $152.96M (59.8%), ahead of Emea at $75.16M (29.4%) and Apac at $26.18M (10.2%). The remaining region, Rest Of World, brought in $1.56M.
Compared with fiscal 2024, United States grew fastest, up 33.2% to $152.96M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $180.96M to $255.87M, a compound annual growth rate of 12.2%. United States' share of the total fell from 68.3% to 59.8%.
Software was Schrodinger’s largest segment in fiscal 2025, bringing in $199.50M of $255.87M (78%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|
| Software | $135.58M | $159.12M | $180.37M | $199.50M | |||
| Drug Discovery | $45.38M | $57.54M | $27.17M | $56.37M | |||
| Total | $180.96M | $216.67M | $207.54M | $255.87M |
Schrodinger brought in $255.87M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 23.3% from $207.54M in fiscal 2024. Software was the largest at $199.50M (78.0%), ahead of Drug Discovery at $56.37M (22.0%).
Compared with fiscal 2024, Drug Discovery grew 107.4% to $56.37M and Software grew 10.6% to $199.50M. From fiscal 2022 to 2025, combined revenue from these segments grew from $180.96M to $255.87M, a compound annual growth rate of 12.2%. Software's share of the total rose from 74.9% to 78.0%.
Schrodinger (SDGR) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Revenue From Contracts With Customers was its largest product and service line, bringing in $183.51M (72.5% of the total), followed by Drug Discovery Services at $30.00M (11.8%).
Revenue From Contracts With Customers was Schrodinger's largest product and service line in fiscal 2025, bringing in $183.51M, or 72.5% of the $253.25M total across its five product and service lines.
United States was Schrodinger's largest region in fiscal 2025, bringing in $152.96M, or 59.8% of the $255.87M total across its four regions.
Software was Schrodinger's largest segment in fiscal 2025, bringing in $199.50M, or 78.0% of the $255.87M total across its two segments.
Among Schrodinger's regions that make up at least 2% of revenue, United States grew fastest in fiscal 2025, up 33.2% from $114.87M to $152.96M.
Every figure comes from Schrodinger's annual financial filings, as reported. Each line keeps the name Schrodinger gives it, and years follow its fiscal calendar.
Schrodinger's revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.